Abdul Basit, MD
Cardiovascular Disease · Fort Worth, TXNPI 1720081631
Payments from drug & device makers
Across 127 payments — averaging $40.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teleflex LLC$1K
- Boston Scientific$601
- Abbott$464
- Johnson & Johnson$296
- Alnylam Pharmaceuticals Inc.$288
- Abiomed$267
- plus $2K from 22 others
What the payments were for
- Consulting fees$1,20023%
- Speaking & faculty fees$1252%
- Travel & lodging$1613%
- Food & beverage$3,65471%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teleflex LLC | 1 | $1,200 |
| Boston Scientific | 12 | $601 |
| Abbott | 4 | $464 |
| Johnson & Johnson | 26 | $296 |
| Alnylam Pharmaceuticals Inc. | 14 | $288 |
| Abiomed | 2 | $267 |
| Medtronic | 3 | $258 |
| Sanofi-aventis U.S. LLC | 5 | $248 |
| Endologix LLC | 2 | $239 |
| Shockwave Medical, Inc | 6 | $210 |
| Novartis | 11 | $183 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 9 | $175 |
| Sanofi | 1 | $125 |
| Amgen | 7 | $123 |
| Cleerly, Inc. | 2 | $122 |
| Merck | 5 | $70 |
| AstraZeneca | 2 | $35 |
| Cook Medical LLC | 2 | $34 |
| Novo Nordisk | 2 | $32 |
| Inari Medical, Inc. | 2 | $30 |
| Elutia, Inc. | 1 | $21 |
| Cardiovascular Systems Inc. | 2 | $20 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $20 |
| E.r. Squibb & Sons, L.L.C. | 1 | $18 |
| Stryker | 1 | $18 |
| Tactile Systems Technology Inc | 1 | $17 |
| Pfizer | 1 | $14 |
| Scpharmaceuticals Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MANTA$1,200
- Impella$267
- Ovation$239
- PRALUENT$200
- ONYX FRONTIER$172
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$159
- CardioMEMS HF System$146
- CROSSBOSS$140
- Optis Coronary Imaging System$140
- AFX$131
- MULTAQ$125
- GENERAL ANGIOPLASTY$122
How this compares
$5,141 in reported general payments places this provider in the 55th percentile of 1,515 cardiovascular disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 114 | $86,494 |
| BrilintaTicagrelor | 89 | $44,354 |
| XareltoRivaroxaban | 22 | $18,170 |
| Repatha SureclickEvolocumab | 13 | $7,292 |
| Ranolazine ErRanolazine | 82 | $2,981 |
| Atorvastatin Calcium | 214 | $1,943 |
| Carvedilol | 275 | $1,285 |
| Metoprolol Succinate | 173 | $1,159 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 35 | $911 |
| Losartan Potassium | 146 | $888 |
| Prasugrel Hcl | 24 | $814 |
| Flecainide Acetate | 17 | $696 |
| ClopidogrelClopidogrel Bisulfate | 124 | $586 |
| Rosuvastatin Calcium | 90 | $486 |
| Amiodarone Hcl | 11 | $449 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $14 | $86,494114 claims |
| AstraZenecaBrilinta | $35 | $44,35489 claims |
| Johnson & JohnsonXarelto | $296 | $18,17022 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,515 cardiovascular disease providers in Texas.
Other cardiovascular disease in Fort Worth
- Ramin Farzaneh-FarDallas$17.1M
- Jeffrey GladdenDallas$15.8M
- Ann NavarDallas$14.5M
- David BrabhamAmarillo$11.5M
- Justin GrodinDallas$6.2M
- Christie BallantyneHouston$4.6M
- Syed NaqviHouston$3.6M
- Faisal WahidMcKinney$3.4M
- James FeldmanHouston$3.1M
- Fernando BoccalandroOdessa$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.